Combination Of Viral And Bacterial Antigens (e.g., Multivalent Viral And Bacterial Vaccine, Etc.) Patents (Class 424/201.1)
-
Publication number: 20140147475Abstract: The present invention pertains to a vaccine comprising live attenuated Pasteurella multocida bacteria for protection of a ruminant against pneumonia caused by Pasteurella multocida by administration of the vaccine to the upper respiratory tract of the ruminant via atomisation of the vaccine. The invention also pertains to a method to use the vaccine to protect a ruminant against pneumonia caused by Pasteurella multocida bacteria.Type: ApplicationFiled: November 26, 2013Publication date: May 29, 2014Inventor: Antonius Arnoldus Christiaan Jacobs
-
Publication number: 20140134202Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.Type: ApplicationFiled: December 13, 2011Publication date: May 15, 2014Applicant: FOLIA BIOTECH INC.Inventors: Denis LECLERC, Nathalie MAJEAU, Constantino Roberto LOPEZ-MACIAS, III, Alain LAMARRE
-
Publication number: 20140127259Abstract: The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) by using Leptospira interrogans serovar hardjo (type hardjoprajitno).Type: ApplicationFiled: January 13, 2014Publication date: May 8, 2014Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventor: Carol L. RINEHART
-
Publication number: 20140120135Abstract: The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity higher than the osmolarity of a 0.9% (w/v) sodium chloride solution in water. The invention also pertains to the acrylic acid polymer for use in a one shot vaccine against porcine circo virus 2 (PCV2) and optionally Mycoplasma hyopneumoniae and in an aqueous composition for reducing fever induced by the biological antigens present in the aqueous composition when the composition is administered to a subject animal.Type: ApplicationFiled: June 26, 2012Publication date: May 1, 2014Inventor: Erwin Mombarg
-
Publication number: 20140112950Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.Type: ApplicationFiled: March 2, 2012Publication date: April 24, 2014Inventors: Manmohan Singh, Barbara Baudner, David Skibinski
-
Publication number: 20140105930Abstract: Methods for stimulating immune responses in a bovine animal susceptible to infection by Leptospira hardjo-bovis are disclosed. In the methods, a composition of inactivated L. hardjo-bovis and an adjuvant is administered to the animal within about 4 weeks of birth. The immune responses stimulated in the animal prevent or shorten the duration of a subsequent L. hardjo-bovis infection. The immune response is effective for at least a year.Type: ApplicationFiled: June 8, 2012Publication date: April 17, 2014Applicant: NOVARTIS AGInventor: Eric Springer
-
Patent number: 8691234Abstract: Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.Type: GrantFiled: April 27, 2009Date of Patent: April 8, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato
-
Patent number: 8685721Abstract: A surface expression vector for preparing HPV immunogenic compositions, in which the surface expression vector contains a gene encoding a repE mutant protein having an amino acid sequence of SEQ ID NO: 1, a promoter, a poly-gamma-glutamate synthetase complex gene, and a gene which is linked with the poly-gamma-glutamate synthetase complex gene and encodes a tumor induction-associated antigen protein of human papillomavirus. An expression vector constitutively expressing a high level of the human papillomavirus (HPV) antigen protein is provided. Also, a recombinant lactic acid bacteria, transformed with the expression vector and expressing the HPV antigen protein on the surface thereof, and a composition comprising the recombinant lactic acid bacteria are provided. The recombinant lactic acid bacteria and the composition are very effective as a immunogenic composition for the treatment of cervical cancer, because they can be applied orally or directly to the vagina.Type: GrantFiled: January 8, 2010Date of Patent: April 1, 2014Assignees: Bioleaders Corporation, Kookmin University Industry-Academy Cooperation FoundationInventors: Moon-Hee Sung, Haryoung Poo, Il Han Lee
-
Publication number: 20140079733Abstract: Provided herein are compositions comprising a canine influenza virus and a canine respiratory coronavirus. They can further comprise Bordetella bronchiseptica, pertactin, canine parainfluenza virus, and canine adenovirus serotype 2. The compositions are effective for treating or preventing canine respiratory diseases, including canine infectious respiratory disease complex.Type: ApplicationFiled: February 3, 2012Publication date: March 20, 2014Inventors: Omar Yousif Abdelmagid, Joseph Michael Bricker, Shelly Lynn Shields
-
Publication number: 20140079732Abstract: The present invention relates to the field of vaccines. More specifically the present invention relates to compositions and methods for enhancing immune responses induced by vaccines, including vaccines targeted at secondary infections and conditions associated with influenza infection.Type: ApplicationFiled: January 27, 2012Publication date: March 20, 2014Applicant: GAMMA VACCINES PTY LIMITEDInventors: Arno Mullbacher, Mohammed Alsharifi, Tim Hirst, Yoichi Furuya
-
Publication number: 20140037680Abstract: This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) through maternal immunization using recombinant respiratory syncytial virus (RSV) antigens to reduce the incidence or severity of RSV infection in young infants.Type: ApplicationFiled: March 15, 2013Publication date: February 6, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Ann-Muriel STEFF, Jean-Francios TOUSSAINT
-
Patent number: 8642258Abstract: The present invention relates to a product named “immunogenical complex”, which comprises an adjuvant characterized by solid particles of highly ordinated nanostructured mesoporous silica, preferably, SBA-15 Silica, and vaccinal antigens of several natures, encapsulated in the referred to adjuvants. The immunogenical complex of the present invention allows the presentation of the antigens that compose it to lymphocytes, in a safe, gradual and extended way, which leads to a more efficient immunological memory, increases the immunogenicity of the antigen and improves the production of antibodies. This ensures an efficient immunological protection with fewer amounts of antigens and/or less repetitions of vaccinal doses. In addition, the characteristics of the immunogenical complex of the present invention promotes effective immunity induction, homogeneous in “god and bad respondent” individuals.Type: GrantFiled: September 12, 2006Date of Patent: February 4, 2014Assignees: Cristalia Produtos Quimicos Farmaceuticos Ltda., Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FapespInventors: Ogari Pacheco, Osvaldo Augusto Sant'Anna, Lucildes Mercure, Jivaldo Matos, Márcia Fantini
-
Publication number: 20140030342Abstract: The present invention relates to the field of vaccines for protecting against tetanus, and in particular processes for the production of vaccines comprising tetanus toxoid adsorbed onto aluminium salts. Processes are provided whereby tetanus toxoid is absorbed onto aluminium salt adjuvant having defined characteristics for optimal results.Type: ApplicationFiled: April 5, 2012Publication date: January 30, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Koen De-Heyder, Olivier Staudt
-
Patent number: 8637046Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.Type: GrantFiled: October 1, 2009Date of Patent: January 28, 2014Assignees: Cornell University, Novartis AGInventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
-
Publication number: 20140023678Abstract: The present invention provides compositions and methods for eliciting protective immunity in animals against Leptospira Interrogans (LI) serovar copenhageni. The invention is based, in part, on the unexpected cross-protection against heterologous LI serovar, which resulted when canines were administered an effective amount of RECOMBITEK® 4 Lepto, then subsequently challenged with virulent L. copenhageni (Fiocruz L1-130).Type: ApplicationFiled: July 11, 2013Publication date: January 23, 2014Applicant: MERIAL LIMITEDInventor: Maria Camila Pardo
-
Publication number: 20140004144Abstract: The present invention provides attenuated S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides novel, mutagenically-induced mutations in S. suis genes, which are useful in the production of novel attenuated S. suis bacterial strains.Type: ApplicationFiled: June 24, 2013Publication date: January 2, 2014Applicant: MERIAL LIMITEDInventors: Russell F Bey, Paulraj Kirubakaran Lawrence, Randy R Simonson, Kamesh Reddy Sirigireddy, Danielle A McKeown
-
Publication number: 20130337006Abstract: The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.Type: ApplicationFiled: June 17, 2013Publication date: December 19, 2013Inventors: Nathalie Marie-Josephe GARCON, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Publication number: 20130337007Abstract: The present invention relates to Salmonid alphavirus E2-protein expressed in a bacterial expression system, its use in medicine, vaccines comprising such protein, methods for the preparation of such proteins and methods for the preparation of vaccines comprising such proteins.Type: ApplicationFiled: December 28, 2011Publication date: December 19, 2013Inventor: Stephane Villoing
-
Publication number: 20130315951Abstract: The invention provides for oral compositions for safely stimulating an immune response to mucoadhesive antigens for protection against infectious agents, particularly influenza viruses using heat-labile, mutant Escherichia coli enterotoxins and antigen. Methods of stimulating immune responses and for eliciting IgA antibodies are also provided.Type: ApplicationFiled: November 6, 2012Publication date: November 28, 2013Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: John D. Barackman, Gary Ott, Samuel Pine, Derek O'hagan
-
Publication number: 20130302369Abstract: Provided herein are compositions, combinations, and methods comprising Bordetella bronchiseptica and isolated pertactin, which are effective in treating or preventing respiratory infections, such as kennel cough, in animals.Type: ApplicationFiled: February 3, 2012Publication date: November 14, 2013Inventors: Omar Yousif Abdelmagid, Joseph Michael Bricker, Shelly Lynn Shields, Jeffrey E. Galvin
-
Patent number: 8574589Abstract: Bordetella pertussis p69 antigen is purified by immobilized metal affinity chromatography.Type: GrantFiled: May 10, 2010Date of Patent: November 5, 2013Assignee: Novartis AGInventor: Christian A. Lease
-
Patent number: 8574588Abstract: Fusion proteins comprise at least a portion of at least one flagellin and at least a portion of at least one Dengue viral envelope protein. The fusion proteins are used to stimulate an immune response and protective immunity in a subject.Type: GrantFiled: July 18, 2007Date of Patent: November 5, 2013Assignee: VanInnate CorporationInventors: Thomas J. Powell, Valerian Nakaar, Langzhou Song, James W. Huleatt, William F. McDonald, Duane D. Hewitt
-
Patent number: 8568738Abstract: The invention relates to virus-modified bacteria ghosts and the use thereof, for example, as carrier and targeting vehicles for active ingredients.Type: GrantFiled: July 28, 2008Date of Patent: October 29, 2013Inventor: Werner Lubitz
-
Patent number: 8563002Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.Type: GrantFiled: December 23, 2008Date of Patent: October 22, 2013Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Patrick Rheault, Jean-Louis Ruelle
-
Publication number: 20130273100Abstract: The present invention pertains to vaccines suitable for administering systemically that comprise live aro mutant bacteria, an adjuvant, an aromatic supplement, or both an adjuvant and an aromatic supplement. The present invention also pertains to the manufacture of such a vaccine and a method of protecting an animal by administration of the vaccine.Type: ApplicationFiled: December 21, 2011Publication date: October 17, 2013Inventors: Kevin A. O'Connell, Rhonda LaFleur, Huchappa Gowda Jayappa, Terri A. Wasmoen
-
Publication number: 20130266603Abstract: This invention provides a trivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M. hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a PRRS virus antigen, wherein the soluble portion of the M. hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.Type: ApplicationFiled: March 26, 2013Publication date: October 10, 2013Applicant: Zoetis LLCInventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
-
Publication number: 20130266602Abstract: This invention provides a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M. hyo) whole cell preparation; and a porcine circovirus type 2 (PCV2) antigen, wherein the soluble portion of the M. hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.Type: ApplicationFiled: March 26, 2013Publication date: October 10, 2013Applicant: Zoetis LLCInventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
-
Publication number: 20130266601Abstract: This invention provides an immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.Type: ApplicationFiled: March 26, 2013Publication date: October 10, 2013Applicant: Zoetis LLCInventors: Jeffrey E. Galvin, Gregory P. Nitzel, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
-
Patent number: 8551451Abstract: The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.Type: GrantFiled: October 23, 2009Date of Patent: October 8, 2013Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
-
Publication number: 20130251745Abstract: The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventors disclose that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicant: Glaxosmithkline Biologicals S.A.Inventor: JAN POOLMAN
-
Publication number: 20130236492Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.Type: ApplicationFiled: March 8, 2013Publication date: September 12, 2013Applicant: NOVARTIS AGInventors: Barbara BAUDNER, Derek O'HAGAN, Manmohan SINGH, Simone BUFALI
-
Patent number: 8529906Abstract: The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.Type: GrantFiled: June 1, 2010Date of Patent: September 10, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Manmohan Singh
-
Publication number: 20130224266Abstract: The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a Shigella outer membrane protein (OMP) and Shigella LPS molecule in medicine and methods for preparing the composition.Type: ApplicationFiled: October 27, 2011Publication date: August 29, 2013Applicant: GlaxoSmithKline Biologicals S.A.Inventors: Normand Blais, Anne-Marie Lanteigne, Daniel Larocque, Corey Patrick Mallett
-
Publication number: 20130195892Abstract: The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.Type: ApplicationFiled: September 21, 2011Publication date: August 1, 2013Inventors: Martin Beer, Ilona Reimann, Patricia Koenig
-
Publication number: 20130195913Abstract: The invention relates to live attenuated parvoviruses, their uses, vaccines comprising such live attenuated parvoviruses, as well as methods for their production.Type: ApplicationFiled: July 18, 2011Publication date: August 1, 2013Inventor: Norman Spibey
-
Patent number: 8491915Abstract: Heat treated bacterins, a method of producing heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins are disclosed.Type: GrantFiled: September 7, 2007Date of Patent: July 23, 2013Assignee: AH USA 42 LLCInventors: Mark D. Goodyear, Michael J. Huether, Ramasamy M. Mannan, Nancee L. Oien
-
Publication number: 20130183338Abstract: The present invention pertains to a vaccine comprising in combination non-live antigens of Lawsonia intracellularis, of Mycoplasma hyopneumniae and Porcine circo virus, and a pharmaceutically acceptable carrier. The invention also pertains to a kit comprising a first container having contained therein non-live antigens of Lawsonia intracellularis, one or more other containers having contained therein Mycoplasma hyopneumoniae and Porcine circo virus antigens and instructions for mixing the antigens of Lawsonia intracellularis, Mycoplasma hyopneumoniae, and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination.Type: ApplicationFiled: February 5, 2013Publication date: July 18, 2013Inventors: Antonius Arnoldus Christiaan Jacobs, Paul VERMEIJ, Ruud Philip Antoon Maria SEGERS, Carla Christina SCHRIER
-
Publication number: 20130183337Abstract: A kit, a method of using it and a process for preparing a vaccine for immunization against the disease Porcine Circovirus Disease and/or Enzootic Pneumonia in pigs are proposed, in which a first container is only partly filled with a first vaccine and a second container is filled with a second vaccine, the second vaccine being transferred into the first container through an adapter device, when a closure device is penetrated for the first and/or only time, and the vaccinating agent is prepared therein, thus making the operation simple, less error-prone and more hygienic, while reducing the materials required. The adapter device has a pair of oppositely facing piercing elements formed of one of needles, hollow, spikes, wedges with at least one through passage extending through both piercing elements, each of the containers being pierced by a respective one of the piercing elements creating a fluid connection between the containers.Type: ApplicationFiled: January 14, 2013Publication date: July 18, 2013Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Boehringer Ingelheim Vetmedica GmbH
-
Patent number: 8460679Abstract: This invention relates to compositions and methods of preparing stable adjuvant diluent stock solutions and final adjuvant solutions comprising glycolipids, weak acids, alcohols, nonionic surfactants and buffers.Type: GrantFiled: January 26, 2007Date of Patent: June 11, 2013Assignee: Zoetis LLCInventors: Ramasamy M. Mannan, Paul J. Dominowski, Sangita Mediratta
-
Patent number: 8444992Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: GrantFiled: September 4, 2012Date of Patent: May 21, 2013Assignee: Novartis Vaccines and Diagnostics GmbHInventor: Astrid Borkowski
-
Publication number: 20130122040Abstract: The present invention relates to a fermentation medium for cultivating Corynebacterium diphtheriae. The present invention also relates to the use of the fermentation medium in processes for obtaining diphtheria toxin from the Corynebacterium diphtheriae bacteria being cultivated and the preparation of vaccines using the diphtheria toxin obtained in the processes. The present invention further relates to a purification and detoxification processes specifically adapted for preparing a diphtheria toxoid for inclusion into a vaccine.Type: ApplicationFiled: November 9, 2012Publication date: May 16, 2013Applicant: NOVARTIS AGInventor: Novaritis AG
-
Publication number: 20130122041Abstract: The present invention relates to an attenuated strain of Ehrlichia canis and a vaccine comprising said attenuated strain for protection of mammals against ehrlichiosis. The invention further relates to methods of preventing ehrlichiosis and of attenuating the pathogenicity Ehrlichia canis.Type: ApplicationFiled: December 31, 2012Publication date: May 16, 2013Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventor: Yissum Research Development Company of the Hebrew University of Jerusalem LTD
-
Patent number: 8440203Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.Type: GrantFiled: November 6, 2009Date of Patent: May 14, 2013Assignee: Intervet Inc.Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
-
Patent number: 8431139Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: May 16, 2006Date of Patent: April 30, 2013Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter InstituteInventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
-
Patent number: 8420102Abstract: Methods of making and compositions that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a membrane fusion domain, a transmembrane domain and a cytoplasmic domain. Compositions can further include a Toll-like Receptor agonist and a carrier protein.Type: GrantFiled: March 6, 2007Date of Patent: April 16, 2013Assignee: VaxInnate CorporationInventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
-
Patent number: 8409587Abstract: The present invention relates to immunogenic compositions comprising a dried solid or highly viscous liquid formulation of inactivated polio virus (IPV) and a stabilizing agent wherein the IPV retains its antigenicity and/or immunogenicity. Methods of producing a dried formulation of IPV which retains its antigenicity/immunogenicity are described.Type: GrantFiled: October 30, 2003Date of Patent: April 2, 2013Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Yves Mayeresse, Jean Stephenne
-
Patent number: 8404247Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: June 23, 2011Date of Patent: March 26, 2013Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Patent number: 8398993Abstract: The present invention describes an immunogenic formulation to be used in mammals against the respiratory syncytial virus (RSV), consisting in the Calmette-Guérin bacillus (BCG) strain or other attenuated Mycobacterium strain that expresses heterologously at least one protein or immunogenic fragment of the RSV subtype A or RSV subtype B strains, originated from proteins NS1, NS2, N, P, M, SH, M2 (ORF1), M2 (ORF2), L, F or G. The genetic material that encodes for these proteins or immunogenic fragments is inserted into the BCG genome or extrachromosomally in one or several copies, which expression is regulated by endogenous or exogenous BCG promoters, either constitutive or inducible. The viral proteins or immunogenic fragments can be expressed by BCG as cytoplasmic-soluble, extracellularly-secreted or cell membrane-bound proteins. The preparation can further contain combinations of previously described formulations. The formulation can be stabilized by freeze-drying (conservation range from 4° C. and 25° C.Type: GrantFiled: September 17, 2008Date of Patent: March 19, 2013Assignee: Pontificia Universidad Catolica de ChileInventors: Alexis Mikes Kalergis Parra, Pablo Alberto Gonzalez Munoz, Susan Marcela Bueno Ramirez
-
Patent number: 8398983Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ug.Type: GrantFiled: June 23, 2006Date of Patent: March 19, 2013Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 8398992Abstract: The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.Type: GrantFiled: December 22, 2011Date of Patent: March 19, 2013Assignee: Polytopos LLCInventors: Michael W Deem, Jeong-Man Park, Hao Zhou